Pharma BD Deal Intelligence

AstraZeneca PLC (MedImmune) / Spirogen Limited

2013 · Acquisition/Merger · $440M · Complete

Announcement Sentiment

100

Strongly positive

MedImmune acquired Spirogen for $200M upfront + up to $240M milestones (total $440M); added PBD-warhead ADC platform plus ADC Therapeutics joint development of two preclinical programs.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Oct 15, 2013
Closed Oct 15, 2013
Deal value $440M
Deal type Acquisition/Merger
Therapeutic area Oncology (ADC platform)
Indications Oncology (ADC platform)
Key assets PBD (pyrrolobenzodiazepine) ADC warhead technology + ADC Therapeutics co-dev
Mechanism Pyrrolobenzodiazepine DNA cross-linking ADC payload chemistry

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals